Home › Research › Biomarkers
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, Lott I, Carroll S et al.. Molecular neurodegeneration, 2020-11-23
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction Tau pathology is a major age-related event in Down syndrome with Alzheimer's disease (DS-AD). Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathies. They have not been yet investigated in tissue obtained postmortem for DS-AD cases. Here, we evaluated the binding characteristics of two Tau PET tracers ( 3 H-MK6240 and 3 H-THK5117) and one amyloid ( 3 H-PIB) ligand in the medial frontal gyrus (MFG) and hippocampus (HIPP) in tissue from adults with DS-AD and DS cases with mild cognitive impairment (MCI) compared to sporadic AD. Methods Tau and amyloid autoradiography were performed on paraffin-embedded sections. To confirm respective ligand targets, adjacent sections were immunoreacted for phospho-Tau (AT8) and stained for amyloid staining using Amylo-Glo. Results The two Tau tracers showed a significant correlation with each other and with AT8, suggesting that both tracers were binding to Tau deposits. 3 H-MK6240 Tau binding correlated with AT8 immunostaining but to a lesser degree than the 3 H-THK5117 tracer, suggesting differences in binding sites between the two Tau tracers. 3 H-THK5117, 3 H-MK6240 and 3 H-PIB displayed dense laminar binding in the HIPP and MFG in adult DS brains. A regional difference in Tau binding between adult DS and AD was observed suggesting differential regional Tau deposition in adult DS compared to AD, with higher THK binding density in the MFG in adult with DS compared to AD. No significant correlation was found between 3 H-PIB and Amylo-Glo staining in adult DS brains suggesting that the amyloid PIB tracer binds to additional sites. Conclusions This study provides new insights into the regional binding distribution of a first-generation and a second-generation Tau tracer in limbic and neocortical regions in adults with DS, as well as regional differences in Tau binding in adult with DS vs. those with AD. These findings provide new information about the binding properties of two Tau radiotracers for the detection of Tau pathology in adults with DS in vivo and provide valuable data regarding Tau vs. amyloid binding in adult DS compared to AD.
What this study adds
Evidence grade: Low
In postmortem brain tissue from adults with Down syndrome and Alzheimer's disease, two tau PET tracers bound to tau deposits and correlated with AT8 immunostaining, with some differences between the tracers. This is laboratory work on tracer binding and does not treat, cure or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Simic, G., Doran, E., et al. (2020). Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Molecular neurodegeneration. https://doi.org/10.1186/s13024-020-00414-3
Vancouver
Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, et al. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Molecular neurodegeneration. 2020. doi:10.1186/s13024-020-00414-3. PMID: 33222700.
BibTeX
@article{lemoine2020-33222700,
author = {Lemoine, L. and Ledreux, A. and Mufson, E. J. and Perez, S. E. and Simic, G. and Doran, E. and Lott, I. and Carroll, S. and others},
title = {{Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue}},
journal = {Molecular neurodegeneration},
year = {2020},
doi = {10.1186/s13024-020-00414-3},
pmid = {33222700},
url = {https://doi.org/10.1186/s13024-020-00414-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Here, we evaluated the binding characteristics of two Tau PET tracers ( 3 H-MK6240 and 3 H-THK5117) and one amyloid ( 3 H-PIB) ligand in the medial frontal gyrus (MFG) and hippocampus (HIPP) in tissue from adults with DS-AD and DS cases with mild cognitive impairment (MCI) compared to sporadic AD.
- Results The two Tau tracers showed a significant correlation with each other and with AT8, suggesting that both tracers were binding to Tau deposits. 3 H-MK6240 Tau binding correlated with AT8 immunostaining but to a lesser degree than the 3 H-THK5117 tracer, suggesting differences in binding sites between the two Tau tracers. 3 H-THK5117, 3 H-MK6240 and 3 H-PIB displayed dense laminar binding in the HIPP and MFG in adult DS brains.
- A regional difference in Tau binding between adult DS and AD was observed suggesting differential regional Tau deposition in adult DS compared to AD, with higher THK binding density in the MFG in adult with DS compared to AD.
- No significant correlation was found between 3 H-PIB and Amylo-Glo staining in adult DS brains suggesting that the amyloid PIB tracer binds to additional sites.
- These findings provide new information about the binding properties of two Tau radiotracers for the detection of Tau pathology in adults with DS in vivo and provide valuable data regarding Tau vs. amyloid binding in adult DS compared to AD.
Why it matters
In postmortem brain tissue from adults with Down syndrome and Alzheimer's disease, two tau PET tracers bound to tau deposits and correlated with AT8 immunostaining, with some differences between the tracers. This is laboratory work on tracer binding and does not treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 27 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.4 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 2 / 6 | Cited 2.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author A.-Ch. Granholm: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33222700) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-020-00414-3
- PubMed: 33222700
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.